Purpose: To investigate orthokeratology-related diurnal variations in visual acuity, contrast sensitivity, mesopic (twilight) vision, and glare sensitivity, and to verify compliance with requirements for driver licensing.
Methods: In this prospective, multicenter, controlled study, fifty myopic (range, -1.00 to -4.50 D) and non-presbyopic glasses or soft contact lens wearers (age range, 16-39 years) were fitted with orthokeratology (OK) contact lenses. Before and after completion of OK lens fitting, measurements of visual acuity, contrast sensitivity, mesopic vision and glare sensitivity were performed at three times of the day, morning, afternoon and evening using a standardized binocular vision testing device (Oculus Binoptometer 4P). Monocular and binocular visual acuity were tested according to ISO 8596 and compared to requirements of cars and motorcycles drivers in different countries.
Results: Compared to the prior correction, binocular visual acuity (logMAR) with orthokeratology was statistically significant better in the morning (0.04 ± 0.12; p < 0.05) and afternoon (0.04 ± 0.10; p < 0.05), while the difference was not statistically significant in the evening (p = 0.512). Furthermore, there was no statistically significant difference in contrast sensitivity in the morning (p = 0.813), afternoon (p = 0.742) or evening (p = 0.945). For both mesopic vision and glare sensitivity, there was no statistically significant difference between the contrast levels achieved with orthokeratology compared to the prior correction in the morning (p = 0.083; p = 1.000), afternoon (p = 0.054; p = 0.125) or evening (p = 0.195; p = 0.635). With orthokeratology, no statistically significant diurnal variation was found for binocular visual acuity, contrast sensitivity, mesopic vision or glare sensitivity (p > 0.05).
Conclusions: These results provide evidence, that visual functions of OK lens wearers are stable throughout the day and comparable to the prior correction. Although the visual standards for driving are not uniform within countries, the requirements for visual acuity are met in all of the countries. Mesopic vision and glare sensitivity, which are suggested as other aspects to influence driving performance, also appear to be constant over the course of the day.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clae.2024.102345 | DOI Listing |
Clin Exp Ophthalmol
December 2024
The Save Sight Institute, Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia.
Background: We aimed to describe a 2-year outcome of eyes managed by practitioners benchmarked using a funnel plot by their frequency of treatment using vascular endothelial growth factor (VEGF) inhibitors for naive retinal vein occlusion (RVO).
Methods: A multicentre, international, observational study of 29 doctors in 12 countries managing 1110 eyes with RVO commencing VEGF inhibitors between 1 January 2012-2022 tracked in the Fight Retinal Blindness! registry.
Results: We identified 3 outlying 'intensive' practitioners (managing 350/1110 eyes [32%]), 22 'typical' practitioners (604/1110, [54%]) and 4 outlying 'relaxed' practitioners (156/1110, [14%]) with respective 24-month outcomes in Branch and Central RVO including the primary outcome, mean adjusted change in visual acuity (VA) in BRVO: +16.
Vestn Oftalmol
December 2024
Krasnov Research Institute of Eye Diseases, Moscow, Russia.
Purpose: This study compares the functional outcomes of correction using two different types of aberrational extended depth-of-focus (EDOF) intraocular lenses (IOLs).
Material And Methods: The study was conducted in two standardized groups (20 patients, 20 eyes in each group). Patients in group 1 were implanted EDOF IOL I, in group 2 - EDOF IOL II.
Vestn Oftalmol
December 2024
Krasnov Research Institute of Eye Diseases, Moscow, Russia.
Preparation for cataract surgery in patients with keratoconus (KC) is associated with particular challenges: calculating the optical power of the intraocular lens (IOL), selecting the appropriate IOL model, and considering additional interventions aimed at stabilizing KC and reducing irregular astigmatism. This article presents a fundamentally new approach to combined treatment of KC with cataract, consisting of two stages: first, performing bandage therapeutic-optical keratoplasty (BTOK), followed by cataract phacoemulsification as the second stage.
View Article and Find Full Text PDFThe introduction of faricimab, a drug targeting both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2, has enabled the implementation of the highly effective dual inhibition strategy in real clinical practice for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both previously treated with intravitreal injections and newly diagnosed. This article presents a series of 11 clinical cases involving patients with nAMD and DME who received loading doses of faricimab and continued ophthalmological observation. Among them, three patients with nAMD and two with DME were treatment-naïve, while the others were switched from alternative therapies to faricimab.
View Article and Find Full Text PDFUnlabelled: Diabetic macular edema (DME) is a leading cause of visual impairment and blindness among diabetic patients, its prevalence is continuing to increase worldwide. Faricimab, a bispecific antibody, represents a new generation of treatments for DME.
Purpose: This study presents an indirect comparison of the effectiveness and safety of faricimab versus other treatment options for DME.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!